Genzyme Corp said the U.S. Patent Officehas approved a patent for the company's method of testing forserum alpha amylase, an indicator of pancreatic disease.    "The patent strengthens Genzyme's proprietary position asthe leading independent supplier of diagnostic enzymes andsubstrates," Henri Temeer, Genzyme president, said.    The company said the technology combines a unique substratewith two indicator enzymes in a diagnostic assay to measureserum amylase levels.    Genzyme said that since 1985 it has entered into severallicensing agreements for the technology with amylase test kitmakers. Reuter&#3;